Patient Satisfaction Following Intrathecal Targeted Drug Delivery for Benign Chronic Pain: Results of a Single‐Center Survey Study

Targeted Drug Delivery (TDD) is commonly used for the management of patients with intractable pain. Past studies have proven efficacy in pain relief and reduction in opioid use and cost‐effectiveness in long‐term pain management. There are few studies investigating satisfaction among patients with implanted pain pumps that are managed with targeted intrathecal medications.

[1]  Neal Shah,et al.  Intrathecal Delivery System , 2019 .

[2]  Kelly K. Haagenson,et al.  Assessment of Health Care Utilization and Cost of Targeted Drug Delivery and Conventional Medical Management vs Conventional Medical Management Alone for Patients With Cancer-Related Pain. , 2019, JAMA network open.

[3]  S. Nagel,et al.  Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome , 2018, Pain medicine.

[4]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[5]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[6]  N. Thompson,et al.  Patient Satisfaction with Collection of Patient-Reported Outcome Measures in Routine Care , 2017, Advances in Therapy.

[7]  E. Buchser,et al.  Comparison of the Effects of Intermittent Boluses to Simple Continuous Infusion on Patients’ Global Perceived Effect in Intrathecal Therapy for Pain: A Randomized Double-Blind Crossover Study , 2016, Pain medicine.

[8]  U. Kallenbach,et al.  Applying a Part of the Daily Dose as Boli May Improve Intrathecal Opioid Therapy in Patients With Chronic Pain , 2016, Neuromodulation : journal of the International Neuromodulation Society.

[9]  D. Caraway,et al.  Successful Discontinuation of Systemic Opioids After Implantation of an Intrathecal Drug Delivery System , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[10]  T. Deer,et al.  Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[11]  M. Saulino,et al.  Systemic Opioid Elimination After Implantation of an Intrathecal Drug Delivery System Significantly Reduced Health‐Care Expenditures , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[12]  N. Mekhail,et al.  Longevity and Cost of Implantable Intrathecal Drug Delivery Systems for Chronic Pain Management: A Retrospective Analysis of 365 Patients , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[13]  P. Christo,et al.  Current perspectives on intrathecal drug delivery , 2014, Journal of pain research.

[14]  G. Kitas,et al.  Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain , 2013, BMJ Open.

[15]  J. Prager,et al.  Medical cost impact of intrathecal drug delivery for noncancer pain. , 2013, Pain medicine.

[16]  G. Rowe,et al.  Patients’ experiences of their healthcare in relation to their expectations and satisfaction: a population survey , 2013, Journal of the Royal Society of Medicine.

[17]  N. Mekhail,et al.  SPINE SECTION Original Research Article Combination of Intrathecal Opioids with Bupivacaine Attenuates Opioid Dose Escalation in Chronic Noncancer Pain Patients , 2016 .

[18]  D. Turk,et al.  Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. , 2010, Pain medicine.

[19]  P. White,et al.  Improvement in Psychosocial Outcomes in Chronic Pain Patients Receiving Intrathecal Morphine Infusions , 2009, Anesthesia and analgesia.

[20]  K. Todd,et al.  The Impact of Pain on Quality of Life and the Unmet Needs of Pain Management: Results From Pain Sufferers and Physicians Participating in an Internet Survey , 2008, American journal of therapeutics.

[21]  E. Buchser,et al.  Patient‐Controlled Analgesia in Chronic Pain Patients: Experience with a New Device Designed to be Used with Implanted Programable Pumps , 2008, Pain practice : the official journal of World Institute of Pain.

[22]  B. Alperson,et al.  Perceived Success and Failure of Intrathecal Infusion Pump Implantation in Chronic Pain Patients , 2008, Neuromodulation : journal of the International Neuromodulation Society.

[23]  M. Saltari,et al.  Continuous Intrathecal Morphine Infusion in Patients With Vertebral Fractures Due to Osteoporosis , 2007, The Clinical journal of pain.

[24]  T. Ness,et al.  Multidimensional Outcomes Analysis of Intrathecal, Oral Opioid, and Behavioral–Functional Restoration Therapy for Failed Back Surgery Syndrome: A Retrospective Study With 4 Years’ Follow‐up , 2006, Neuromodulation : journal of the International Neuromodulation Society.

[25]  L. Webster,et al.  A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. , 2006, Journal of pain and symptom management.

[26]  M. Byas-Smith,et al.  Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial , 2006, Neuromodulation : journal of the International Neuromodulation Society.

[27]  L. Tonder,et al.  Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. , 2004, Pain medicine.

[28]  M. Byas-Smith,et al.  Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. , 2004, JAMA.

[29]  K. Burchiel,et al.  A Prospective, Randomized Trial of Intrathecal Injection vs. Epidural Infusion in the Selection of Patients for Continuous Intrathecal Opioid Therapy , 2003, Neuromodulation : journal of the International Neuromodulation Society.

[30]  N. Rainov,et al.  Patient‐controlled Analgesia in Intrathecal Therapy for Chronic Pain: Safety and Effective Operation of the Model 8831 Personal Therapy Manager with a Pre‐implanted SynchroMed Infusion System , 2003, Neuromodulation : journal of the International Neuromodulation Society.

[31]  L. J. Roberts,et al.  Outcome of intrathecal opioids in chronic non‐cancer pain , 2001, European journal of pain.

[32]  N. Rainov,et al.  Long-term intrathecal infusion of drug combinations for chronic back and leg pain. , 2001, Journal of pain and symptom management.

[33]  M. Kelly,et al.  Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. , 2001, Surgical neurology.

[34]  S. Rutkowski,et al.  The Efficacy of Intrathecal Morphine and Clonidine in the Treatment of Pain After Spinal Cord Injury , 2000, Anesthesia and analgesia.

[35]  B. V. van Hilten,et al.  Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. , 2000, The New England journal of medicine.

[36]  D. Doleys,et al.  Use of Intraspinal Infusion Therapy with Non‐Cancer Pain Patients: Follow‐up and Comparison of Worker's Compensation vs. Non‐Worker's Compensation Patients , 1998, Neuromodulation : journal of the International Neuromodulation Society.

[37]  W. Winkelmüller,et al.  Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. , 1996, Journal of neurosurgery.

[38]  D. V. Nelson,et al.  Psychological selection criteria for implantable spinal cord stimulators , 1996 .

[39]  D. Doleys,et al.  Intrathecal Infusion Systems for Treatment of Chronic Low Back and Leg Pain of Noncancer Origin , 1996, Southern medical journal.

[40]  S. Hassenbusch,et al.  Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. , 1995, Journal of pain and symptom management.

[41]  T. Yaksh,et al.  Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. , 1981, Mayo Clinic proceedings.